PROLONGED SURVIVAL IN HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) PATIENTS (PTS) WITH-7/DEL(7Q) TREATED WITH AZACITIDINE (AZA)

被引：0
|
作者：
Mufti, G. J. [1 ]
Garcia-Manero, G. [2 ]
Hovarth, N. [3 ]
Lim, Z. [4 ]
Quesnel, B. [5 ]
Leone, G. [6 ]
Bennett, J. [7 ]
Sanz, G. [8 ]
McKenzie, D. [9 ]
Backstrom, J. [9 ]
Beach, C. L. [9 ]
机构：
[1] Kings Coll Hosp London, London, England
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] IMVS, Adelaide, SA, Australia
[4] Kings Coll London, London WC2R 2LS, England
[5] CHU Lille, Serv Malad Sang, F-59037 Lille, France
[6] Policlin Gemelli, Div Ematol, Rome, Italy
[7] Univ Rochester, Rochester, NY 14627 USA
[8] Hosp Univ La Fe, Inst Name, Valencia, Spain
[9] Pharm Corp, Overland Pk, KS USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0928
引用
收藏
页码：369 / 370
页数：2
相关论文
共 50 条
  • [1] Treatment of high-risk MDS patients (pts) with-7/del(7q) with azacitidine (AZA) versus conventional care regimens (CCR): Effects on overall survival (OS)
    Mufti, G. J.
    Fenaux, P.
    Hellstrom-Lindberg, E.
    Santini, V.
    List, A. F.
    Gore, S.
    Seymour, J. F.
    Silverman, L. R.
    Backstrom, J.
    Beach, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)
    Silverman, Lewis R.
    Fenaux, Pierre
    Mufti, Ghulam J.
    Santini, Valeria
    Hellstrom-Lindberg, Eva
    Gattermann, Norbert
    Sanz, Guillermo
    List, Alan F.
    Gore, Steven D.
    Seymour, John F.
    Backstrom, Jay
    McKenzie, David
    Beach, C. L.
    BLOOD, 2008, 112 (11) : 91 - 91
  • [3] EFFECT OF AZACITIDINE (AZA) ON TRANSFUSION INDEPENDENCE (TI) AND OVERALL SURVIVAL IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES
    Seymour, J.
    Santini, V.
    Fenaux, P.
    Giagounidis, A.
    Sanz, G.
    List, A. F.
    McKenzie, D.
    Backstrom, J.
    Beach, C. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 328 - 328
  • [4] Patient outcome measures during prolonged survival in patients (Pts) with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA)
    Santini, V.
    Fenaux, P.
    Mufti, G. J.
    Hellstroem-Lindberg, E.
    List, A. F.
    Silverman, L. R.
    Seymour, J. F.
    Backstrom, J.
    McKenzie, D.
    Beach, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission
    List, A. F.
    Fenaux, P.
    Mufti, G. J.
    Hellstroem-Lindberg, E.
    Gore, S.
    Bennett, J. M.
    Silverman, L. R.
    Backstrom, J.
    Allen, A. R.
    Beach, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine
    Bouchla, Anthi
    Thomopoulos, Thomas P.
    Papageorgiou, Sotirios G.
    Apostolopoulou, Christina
    Loucari, Constantinos
    Mpazani, Efthimia
    Pappa, Vasiliki
    EPIGENOMICS, 2021, 13 (14) : 1129 - 1143
  • [7] Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA)
    Santini, Valeria
    Fenaux, Pierre
    Mufti, Ghularn J.
    Hellstrom-Lindberg, Eva
    Silverman, Lewis B.
    List, Alan
    Gore, Steven D.
    Seymour, John F.
    Backstrom, Jay
    McKenzie, David
    Beach, C. L.
    BLOOD, 2008, 112 (11) : 583 - 584
  • [8] Time-dependent decision analysis: Stable disease in azacitidine (AZA)-treated patients (pts) with higher-risk MDS
    Gore, S.
    Fenaux, P.
    Santini, V.
    Bennett, J. M.
    Silverman, L. R.
    Seymour, J. F.
    Hellstrom-Lindberg, E.
    Swern, A. S.
    Beach, C. L.
    List, A. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Counseling Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Regarding Expected Survival with Azacitidine (aza) Therapy: Are We Using Accurate Estimates?
    Deveaux, Michelle
    Stahl, Maximilian
    Giri, Smith
    Wang, Rong
    Podoltsev, Nikolai A.
    Ma, Xiaomei
    Zeidan, Amer M.
    BLOOD, 2017, 130
  • [10] Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome
    Cordoba, Iris
    Gonzalez-Porras, Jose R.
    Nomdedeu, Benet
    Luno, Elisa
    de Paz, Raquel
    Such, Esperanza
    Tormo, Mar
    Vallespi, Teresa
    Collado, Rosa
    Xicoy, Blanca
    Andreu, Rafael
    Munoz, Juan A.
    Sole, Francesc
    Cervera, Jose
    del Canizo, Consuelo
    CANCER, 2012, 118 (01) : 127 - 133
12345